PMID: 29112560
Question: Is the Distance Worth It?
Correct Answer: yes

======================= Launch the MCC process =======================
PMID: 29112560
Question: Is the Distance Worth It?

----- GPT's initial response -----
GPT is reasoning the answer...


**1. Question Analysis**
The core question is whether the benefits of traveling long distances to high-volume medical centers for rectal cancer resection outweigh the burdens associated with such travel. Key information to look for includes comparative outcomes between patients treated at high-volume centers versus low-volume centers, specifically focusing on surgical success, postoperative mortality, and long-term survival.

**2. Evidence Evaluation**
The study utilized the National Cancer Database to analyze outcomes for 18,605 patients with stage II or III rectal cancer who underwent surgical resection between 2006 and 2012. The findings indicate that patients who traveled to high-volume centers experienced:

- Improved lymph node yield (OR = 0.51)
- Higher receipt of neoadjuvant chemoradiation (OR = 0.67)
- Lower 30-day (OR = 3.38) and 90-day mortality (OR = 2.07)
- Enhanced 5-year overall survival (34% high risk of mortality compared to long-distance group)

The large sample size and population-based nature of the study enhance the reliability of the evidence. Additionally, controlling for patient, tumor, and hospital factors strengthens the validity of the conclusions.

**3. Conclusion**
The evidence strongly supports that traveling to high-volume centers for rectal cancer surgery leads to better clinical outcomes, including higher survival rates and lower mortality, which outweigh the inconveniences of long-distance travel.

**4. Final Answer:**
**My final choice is: "yes"**
GPT selected: yes

----- Qwen's initial response -----
Qwen is reasoning the answer...


**1. Question Analysis**  
The question asks whether traveling long distances to high-volume centers for rectal cancer resection is worth the burden compared to being treated locally at low-volume centers. The key outcomes to evaluate include surgical quality (margins, lymph node yield), treatment receipt (neoadjuvant chemoradiation, adjuvant chemotherapy), mortality rates, and survival. The study’s results must indicate whether high-volume centers’ benefits outweigh the travel disadvantages.

**2. Evidence Evaluation**  
The study found that patients in the **short-distance/low-volume group** had:  
- **Lower odds** of adequate lymph node yield (OR=0.51) and receipt of neoadjuvant chemoradiation (OR=0.67).  
- **Higher 30-day mortality** (OR=3.38) and **90-day mortality** (OR=2.07).  
- **34% higher risk of 5-year mortality** compared to the long-distance/high-volume group.  

These results were **controlled for patient, tumor, and hospital factors**, strengthening the conclusion that high-volume centers provide superior outcomes. The limitations (e.g., missing data on patient/physician decision-making) do not negate the statistically significant associations observed.

**3. Conclusion**  
The study’s data clearly shows that patients traveling to high-volume centers had significantly better surgical outcomes, survival rates, and reduced mortality, despite the longer distance. The benefits of high-volume centers’ expertise and resources outweigh the travel burden, supporting a "yes" answer.

**4. Final Answer:**  
**My final choice is: "yes"**
Qwen selected: yes

----- Deepseek's initial response -----
DeepSeek is reasoning the answer...

**1. Question Analysis**  
The core question is whether traveling long distances to high-volume centers for rectal cancer resection results in better outcomes compared to receiving local care at low-volume centers. Key factors to assess include surgical outcomes (e.g., lymph node yield, mortality rates) and survival benefits.

**2. Evidence Evaluation**  
The study demonstrates that patients traveling to high-volume centers (median 62.6 miles) had significantly better outcomes:  
- Higher odds of adequate lymph node yield (OR = 0.51 for low-volume centers, indicating worse performance).  
- Greater likelihood of receiving neoadjuvant chemoradiation (OR = 0.67 for low-volume centers).  
- Lower 30-day (OR = 3.38) and 90-day mortality (OR = 2.07) in the high-volume group.  
- 34% higher 5-year overall survival risk for the low-volume group.  
These results are adjusted for patient, tumor, and hospital factors, strengthening reliability. Limitations include missing data on decision-making processes and surgeon-specific variables, but the primary outcomes remain robust.

**3. Conclusion**  
The evidence strongly supports that high-volume centers achieve superior clinical outcomes and survival, outweighing the travel burden. Thus, traveling long distances is likely "worth it" for improved care.

**4. Final Answer**  
**My final choice is: yes**
DeepSeek selected: yes

Initial consensus: All models selected yes